TOKYO — Swiss pharmaceutical giant Roche plans to continue investing in major markets including the U.S. and Japan despite President Donald Trump’s order to lower drug prices, CEO Thomas Schinecker told Nikkei recently, saying that innovation is necess to reduce costs.
While the U.S. president considers imposing tariffs on pharmaceuticals, Roche has announced $50 billion in investments in the country.
